Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a significant decline in short interest in May. As of May 29th, there was short interest totaling 61,636 shares, a decline of 51.3% from the May 14th total of 126,538 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average daily volume of 629,575 shares, the days-to-cover ratio is currently 0.1 days.

Azitra Stock Down 4.2%

NYSEAMERICAN AZTR traded down $0.01 during trading on Friday, reaching $0.21. 211,347 shares of the company traded hands, compared to its average volume of 430,090. The stock’s 50 day moving average price is $0.22 and its two-hundred day moving average price is $0.25. Azitra has a 1-year low of $0.10 and a 1-year high of $2.40.

Azitra (NYSEAMERICAN:AZTR) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24). Equities analysts forecast that Azitra will post -0.25 earnings per share for the current fiscal year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.